Showing 1 to 10 of 44 Clinical Trials
CLINICAL TRIAL
    Trial No
    ClinicalTrials.gov ID
Principal Investigator
Coordinator
A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Subjects With Metastatic Solid Malignancies After Progression on Prior PD-1 Inhibitor Treatment
    SGN35-033 (KEYNOTE B81)
    NCT04609566
     Recruiting
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS  

Head and Neck
Melanoma
Non Small Cells - Lung
Dr. Wilson Miller

Daria Krutauz
  514-340-8222 poste 24301

Rim Hojeij
  514-340-8222 poste 26187
Phase I Trial of Camu Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-Small Cell Lung Cancer and Melanoma
    BR-2021-CamuCamu
    NCT05303493
     Recruiting
CISSS DE LA MONTEREGIE-CENTRE
HOPITAL CHARLES-LE MOYNE  

Melanoma
Non Small Cells - Lung
Dr. Nathalie Daaboul

Marilyn Tessier
  450-466-5000 poste 7691
Phase I Trial of Camu Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-Small Cell Lung Cancer and Melanoma
    BR-2021-CamuCamu
    NCT05303493
     Recruiting
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL  
Melanoma
Non Small Cells - Lung
Dr. Bertrand Routy

Wiam Belkaid
  514-890-8000
A Randomized Phase III Study of Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) in High Risk Patients With Stage I Non-Small Cell Lung Cancer (NSCLC), The STABLE-MATES Trial
    STABLE-MATES Trial (JoLT-Ca)
    NCT02468024
     Recruiting
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL  
Non Small Cells - Lung Dr. Édith Filion

Dr. Moishe Liberman

Adeline Jouquan
  514-890-8000 poste 26214
Study of the function and phenotype of tumor infiltrating lymphocytes in non-small cell lung cancer (Main study)
    QC-CAPRION
    n.d.
     Recruiting
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL  
Non Small Cells - Lung Dr. Moishe Liberman

Adeline Jouquan
  514-890-8000 poste 26214
A Randomized, Phase 3, Open-label Study to Evaluate Sigvotatug Vedotin Compared With Docetaxel in Adult Participants With Previously Treated Non-small Cell Lung Cancer
    SGNB6A-002 (Be6A Lung-01)
    NCT06012435
     Recruiting
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL  
Non Small Cells - Lung Dr. Normand Blais

Chantal Gosselin
  514-890-8000 poste 24892
A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
    M18-868
    NCT04928846
     Recruiting
CISSS DE LA MONTEREGIE-CENTRE
HOPITAL CHARLES-LE MOYNE  

Non Small Cells - Lung Dr. Nathalie Daaboul

Marie-Ève Yelle
  450-466-5000 poste 3281
A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated Advanced Or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
    Krascendo 170
    NCT05789082
     Recruiting
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS  

Non Small Cells - Lung Dr. Jennifer Friedmann

Chadi Zakaria
  514-340-8222 poste 28326
A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects With Advanced or Metastatic PD-L1 High (TPS ?50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations
    TROPION-Lung08
    NCT05215340
     Recruiting
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
HOPITAL SANTA CABRINI OSPEDALE

Non Small Cells - Lung Dr. Michael Palumbo

Sabrina Sanzari
  514-252-6000 poste 6677
A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC).
    eVOLVE-Lung02
    NCT05984277
     Recruiting
CISSS DE CHAUDIERE-APPALACHES
HOTEL-DIEU DE LEVIS

Non Small Cells - Lung Dr. Marie-Ève Boucher

Pierre Bédard
  418-835-7121